Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the efficacy and safety of iron therapy
using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo in the treatment of
participants in heart failure with a reduced ejection fraction and with iron deficiency